Review Article
Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives
Table 1
Current HCV NS3-4A protease inhibitors/drugs in pipeline (/r means boosted by ritonavir).
| Mechanism | Inhibitor name | Genotypic coverage | Daily dosing | Company | Status |
| Reversible covalent inhibitor | Incivek (telaprevir, VX-950) | 1 | Three times | Vertex | Approved | Victrelis (boceprevir, SCH503034) | 1 | Three times | Merck | Approved |
| Noncovalent inhibitor | ABT-450/r | 1 | Once | Abbott | Phase III | Simeprevir (TMC435) | 1, 2, 5, and 6 | Once | Janssen | Phase III | Faldaprevir (BI201335) | 1 | Once | Boehringer Ingelheim | Phase III | Danoprevir (RG7227) | 1 | Twice | Genentech | Phase II | Vaniprevir (MK-7009) | 1 | Twice | Merck | Phase II | MK-5172 | 1, 2 | Once | Merck | Phase II | Asunaprevir (BMS-650032) | 1, 4 | Once | Bristol-Myers Squibb | Phase II | ACH-1625 | 1 | Once | Achillion | Phase II | GS-9256 | 1 | Twice | Gilead | Phase II | ACH-2684 | 1, 3 | Once | Achillion | Phase II | GS-9451 | 1a, 1b | Once | Gilead | Phase II | Narlaprevir/r | 1 | Once | Merck | Phase II | IDX320 | 1, 1b, 3a, and 4a | Once | Idenix | Phase II |
|
|